|
Patients Who May BenefitThose with Type II DiabetesPitavastatin has been studied in several patient types, including those with type II diabetes. |
Pitavastatin 4 mg and Atorvastatin 20 mg lower LDL-C comparably in Patients with Type II Diabetes1
Pitavastatin demonstrated effective LDL-cholesterol lowering of up to 41% with 4 mg pitavastatin compared to 20 mg Lipitor®
(atorvastatin) which showed a 43% decrease in LDL cholesterol.1
|
Statins Can Increase Glucose Levels and HbA1C
Increases in glucose levels and HbA1c have been reported with pitavastatin. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.
Pitavastatin demonstrated a non-significant change in blood glucose levels compared to baseline at both 12 and 44 weeks in contrast to atorvastatin which did show significant increases compared to baseline.1
|
|
* Mean per cent changes in blood glucose from core study baseline to week 12 and to extension study week 44. CI, 95% confidence interval; NS, not significant vs. baseline. *p < 0.05 vs. baseline.
† Seven patients up-titrated their dose of atorvastatin from 20 to 40 mg/day at extension study week 0.
Moderate-Intensity Statins are Class I Recommendation in T2DM2
In patients 40 to 75 years of age with diabetes mellitus and LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L), the 2018 ACC/AHA Guidelines recommend patients to start a moderate-intensity statin therapy, regardless of estimated 10-year ASCVD risk (Class I recommendation)..2
However, the 2018 ACC/AHA Guidelines also indicate that statins modestly increase the risk of incident or statin-associated new-onset diabetes mellitus in individuals with:2
- Predisposing risk factors for diabetes mellitus
- Components of the metabolic syndrome
- Higher-intensity statin use
Help your patient find the Right Statin, Right Away
Zypitamag is accessible like a generic statin.
Click another example of a patient group who may benefit from Zypitamag:
|
Have type II diabetes |
|
|
|
|
|
IMPORTANT SAFETY INFORMATION FOR ZYPITAMAG™ (pitavastatin) tablets
INDICATIONS & USAGE
ZYPITAMAG is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia.
Pediatric use information is approved for Kowa Co Ltd LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd marketing exclusivity rights, this drug product is not labeled with that information.
CONTRAINDICATIONS
ZYPITAMAG is contraindicated in the following conditions:
- Concomitant use of cyclosporine.
- Acute liver failure or decompensated cirrhosis.
- Hypersensitivity to pitavastatin or any excipients in ZYPITAMAG. Hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin.
WARNINGS & PRECAUTIONS
- Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher ZYPITAMAG dosage. ZYPITAMAG is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil. The following drugs when used concomitantly with ZYPITAMAG may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1 g/day), fibrates, and colchicine. Discontinue ZYPITAMAG if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Temporarily discontinue ZYPITAMAG in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis; e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the ZYPITAMAG dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever.
- Immune-Mediated Necrotizing Myopathy (IMNM): There have been rare reports of IMNM, an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue ZYPITAMAG if IMNM is suspected.
- Hepatic Dysfunction: Increases in serum transaminases can occur. Rare postmarketing reports of fatal and non-fatal hepatic failure have occurred. Consider liver enzyme testing before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ZYPITAMAG.
- Increases in HbA1c and Fasting Serum Glucose Levels: Increases of each have been reported with statins, including ZYPITAMAG. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.
ADVERSE REACTIONS: The most frequent adverse reactions (rate ≥ 2%) are myalgia, constipation, diarrhea, back pain, and pain in extremity. This is not a complete list of all reported adverse events.
For additional information, refer to full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
